| Year |
Citation |
Score |
| 2024 |
Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, ... ... Davila ML, et al. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discovery. PMID 38194367 DOI: 10.1158/2643-3230.BCD-23-0056 |
0.365 |
|
| 2023 |
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Science Advances. 9: eadg3919. PMID 37738350 DOI: 10.1126/sciadv.adg3919 |
0.388 |
|
| 2023 |
Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, ... ... Davila ML, et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardio-Oncology (London, England). 9: 18. PMID 37005652 DOI: 10.1186/s40959-023-00170-5 |
0.302 |
|
| 2023 |
Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, ... ... Davila ML, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nature Medicine. PMID 36914893 DOI: 10.1038/s41591-023-02234-6 |
0.381 |
|
| 2023 |
Dong N, Lopes-Garcia LR, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-directed Chimeric Antigen Receptor T-cell Therapy for Transformed Non-follicular Lymphoma. Transplantation and Cellular Therapy. PMID 36878427 DOI: 10.1016/j.jtct.2023.02.021 |
0.37 |
|
| 2023 |
Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. The Lancet. Haematology. 10: e191-e202. PMID 36764323 DOI: 10.1016/S2352-3026(22)00378-7 |
0.309 |
|
| 2022 |
Davila ML, Brentjens RJ. CAR T cell therapy: looking back and looking forward. Nature Cancer. 3: 1418-1419. PMID 36539498 DOI: 10.1038/s43018-022-00484-w |
0.337 |
|
| 2022 |
Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, ... ... Davila M, et al. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Reports. Medicine. 3: 100720. PMID 36384092 DOI: 10.1016/j.xcrm.2022.100720 |
0.309 |
|
| 2022 |
Boucher JC, Yu B, Li G, Shrestha B, Sallman D, Landin AM, Cox C, Karyampudi K, Anasetti C, Davila ML, Bejanyan N. Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 36378147 DOI: 10.1097/CJI.0000000000000445 |
0.388 |
|
| 2022 |
Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, ... ... Davila ML, et al. Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplantation and Cellular Therapy. PMID 36174934 DOI: 10.1016/j.jtct.2022.09.009 |
0.373 |
|
| 2022 |
Aboelella NS, Brandle C, Okoko O, Gazi MY, Ding ZC, Xu H, Gorman G, Bollag R, Davila ML, Bryan LJ, Munn DH, Piazza GA, Zhou G. Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy. Journal For Immunotherapy of Cancer. 10. PMID 35882449 DOI: 10.1136/jitc-2022-004938 |
0.404 |
|
| 2022 |
Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, et al. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances. 6: 3970-3973. PMID 35816359 DOI: 10.1182/bloodadvances.2022007006 |
0.352 |
|
| 2022 |
Jain MD, Ziccheddu B, Coughlin CA, Faramand RG, Griswold AJ, Reid KM, Menges M, Zhang Y, Cen L, Wang X, Hussaini MO, Landgren O, Davila ML, Schatz JH, Locke FL, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. PMID 35476848 DOI: 10.1182/blood.2021015008 |
0.333 |
|
| 2022 |
Li G, Reid KM, Spitler K, Beatty N, Boucher J, Davila ML. CD3 engagement as a new strategy for allogeneic "off-the-shelf" T cell therapy. Molecular Therapy Oncolytics. 24: 887-896. PMID 35317526 DOI: 10.1016/j.omto.2022.02.024 |
0.387 |
|
| 2021 |
Sheikh S, Mokhtari S, Silverman JA, Reid K, Faramand R, Davila ML, Franke N, Locke FL, Jain MD, Wong D, Kuruvilla JG. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. Ejhaem. 3: 223-227. PMID 35846190 DOI: 10.1002/jha2.286 |
0.418 |
|
| 2021 |
Faramand RG, Davila ML. CAR T-cell hematotoxicity: is inflammation the key? Blood. 138: 2447-2448. PMID 34914831 DOI: 10.1182/blood.2021012876 |
0.333 |
|
| 2021 |
Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Journal For Immunotherapy of Cancer. 9. PMID 34706886 DOI: 10.1136/jitc-2021-003354 |
0.355 |
|
| 2021 |
Landin AM, Cox C, Yu B, Bejanyan N, Davila M, Kelley L. Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product. Journal of Visualized Experiments : Jove. PMID 34633380 DOI: 10.3791/62622 |
0.393 |
|
| 2021 |
Davila ML, Bachmeier C. Advances in CAR T cell clinical development. Best Practice & Research. Clinical Haematology. 34: 101307. PMID 34625229 DOI: 10.1016/j.beha.2021.101307 |
0.321 |
|
| 2021 |
Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, et al. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas following Chimeric Antigen Receptor (CAR) T-Cell Therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 34242714 DOI: 10.1016/j.ijrobp.2021.06.038 |
0.38 |
|
| 2021 |
Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 CAR T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma. Transplantation and Cellular Therapy. PMID 34077811 DOI: 10.1016/j.jtct.2021.05.018 |
0.423 |
|
| 2021 |
Wudhikarn K, Flynn JR, Rivière I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, et al. Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy. Blood. PMID 33851211 DOI: 10.1182/blood.2020009515 |
0.432 |
|
| 2021 |
Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, ... Davila ML, et al. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy. 27: 242.e1-242.e6. PMID 33781520 DOI: 10.1016/j.jtct.2020.12.025 |
0.405 |
|
| 2021 |
Boucher JC, Davila ML. Chimeric Antigen Receptor Design Today and Tomorrow. Cancer Journal (Sudbury, Mass.). 27: 92-97. PMID 33750067 DOI: 10.1097/PPO.0000000000000514 |
0.322 |
|
| 2021 |
Bachmeier CA, Kurian TJ, Davila ML. Regulatory challenges and considerations for the clinical application of CAR T cell therapy. Expert Opinion On Biological Therapy. PMID 33555927 DOI: 10.1080/14712598.2021.1887130 |
0.319 |
|
| 2021 |
Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, ... ... Davila ML, et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma. Blood. PMID 33512407 DOI: 10.1182/blood.2020007445 |
0.308 |
|
| 2021 |
Roselli E, Faramand R, Davila ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. The Journal of Clinical Investigation. 131. PMID 33463538 DOI: 10.1172/JCI142030 |
0.395 |
|
| 2021 |
Kumar J, Kumar R, Kumar Singh A, Tsakem EL, Kathania M, Riese MJ, Theiss AL, Davila ML, Venuprasad K. Deletion of Cbl-b inhibits CD8 T-cell exhaustion and promotes CAR T-cell function. Journal For Immunotherapy of Cancer. 9. PMID 33462140 DOI: 10.1136/jitc-2020-001688 |
0.415 |
|
| 2020 |
Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. CD28 co-stimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunology Research. PMID 33188139 DOI: 10.1158/2326-6066.CIR-20-0253 |
0.401 |
|
| 2020 |
Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, et al. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Advances. 4: 4086-4090. PMID 32877523 DOI: 10.1182/Bloodadvances.2020002060 |
0.506 |
|
| 2020 |
Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4: 3268-3276. PMID 32702097 DOI: 10.1182/Bloodadvances.2020001900 |
0.376 |
|
| 2020 |
Faramand RG, Jain MD, Staedtke V, Kotani H, Bai RY, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah BD, Chavez J, ... ... Davila ML, et al. Tumor Microenvironment composition and severe cytokine release syndrome (CRS) Influence Toxicity in Patients with Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32669372 DOI: 10.1158/1078-0432.Ccr-20-1434 |
0.489 |
|
| 2020 |
Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila ML, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. PMID 32614951 DOI: 10.1182/Blood.2020006619 |
0.375 |
|
| 2020 |
Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher JC, Li G, Ghafoor T, Felices M, Miller J, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. The Journal of Clinical Investigation. PMID 32437331 DOI: 10.1172/Jci135754 |
0.464 |
|
| 2020 |
Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, ... ... Davila ML, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. PMID 32327504 DOI: 10.3324/Haematol.2019.238634 |
0.439 |
|
| 2020 |
Sallman DA, Al-Homsi AS, Davila ML, Kerre T, Moors I, Poire X, Havelange V, Lewalle P, Pollyea DA, Wang ES, Blum W, Demoulin B, Sotiropoulou PA, Alcantar-Orozco E, Breman E, et al. Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Blood. 136: 40-41. DOI: 10.1182/blood-2020-139609 |
0.338 |
|
| 2020 |
Sallman DA, Elmariah H, Sweet KL, Talati C, Mishra A, Kelley LL, Lankford A, Chan T, Shah RR, Padron E, Komrokji RS, Lancet JE, Sabzevari H, Davila ML, Bejanyan N. A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome Blood. 136: 17-17. DOI: 10.1182/blood-2020-139417 |
0.405 |
|
| 2020 |
Boucher JC, Yu B, Li G, Shrestha B, Lancet JE, Sallman DA, Landin AM, Mailloux AW, Anasetti C, Kelley LL, Davila ML, Bejanyan N. Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia Blood. 136: 7-8. DOI: 10.1182/blood-2020-136174 |
0.418 |
|
| 2020 |
Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand R, Davila ML, Nieder M, Lawrence N, Lawrence H, Anasetti C, et al. Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results Blood. 136: 48-49. DOI: 10.1182/blood-2020-133874 |
0.304 |
|
| 2020 |
Mokhtari S, Asquith J, Bachmeier C, Faramand R, Kim Y, Peguero E, Sahebjam S, Jain M, Vogelbaum M, Davila M, Forsyth P, Locke F, Aleksandr L. NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY Neuro-Oncology. 22: ii128-ii128. DOI: 10.1093/neuonc/noaa215.538 |
0.351 |
|
| 2020 |
Figura N, Jain M, Sim A, Dean E, Balagurunathan Y, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Kim S, Locke F, Robinson T. OC-0559: Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy Radiotherapy and Oncology. 152: S311-S312. DOI: 10.1016/S0167-8140(21)00581-8 |
0.341 |
|
| 2020 |
Figura N, Jain M, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Kim S, Locke F, Robinson T. Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.589 |
0.444 |
|
| 2020 |
Lazaryan A, Lee S, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Jain MD, Davila ML, Perez LE, Mishra A, et al. Phase II Multicenter Study of Ofatumumab in Combination with Glucocorticoids As a Primary Therapy for Chronic Graft Versus Host Disease Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.743 |
0.354 |
|
| 2020 |
Faramand R, Jain MD, Staedtke V, Bai R, Kotani H, Reid K, Lee S, Chavez JC, Shah BD, Nishihori T, Lazaryan A, Khimani F, Liu H, Bachmeier CA, Dam M, ... ... Davila ML, et al. Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.494 |
0.384 |
|
| 2020 |
Hashmi H, Mirza A, Darwin A, Logothetis C, Garcia F, Kommalapati A, Bachmeier CA, Benson K, Chavez JC, Shah BD, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, et al. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.451 |
0.515 |
|
| 2020 |
Mirza A, Hashmi H, Darwin A, Garcia F, Kommalapati A, Logothetis C, Bachmeier CA, Chavez JC, Shah BD, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, et al. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.431 |
0.505 |
|
| 2020 |
Hashmi H, Mirza A, Darwin A, Logothetis C, Garcia F, Kommalapati A, Bachmeier CA, Chavez JC, Shah BD, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Jain MD, et al. Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.430 |
0.478 |
|
| 2020 |
Ranspach P, Zhou J, Pidala JA, Nishihori T, Nieder ML, Elmariah H, Faramand R, Lazaryan A, Baluch A, Mishra A, Perez LE, Ochoa L, Liu H, Davila ML, Jain MD, et al. Delayed CD4+ T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.409 |
0.473 |
|
| 2020 |
Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, et al. A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.133 |
0.304 |
|
| 2020 |
Shrestha B, Vishwasrao P, Li G, Ghafoor T, Davila ML. Chimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemiachimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemia Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.022 |
0.471 |
|
| 2019 |
Shrestha B, Zhang Y, Yu B, Li G, Boucher JC, Beatty NJ, Tsai HC, Wang X, Mishra A, Sweet K, Lancet JE, Kelley L, Davila ML. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 31834208 DOI: 10.1097/Cji.0000000000000306 |
0.514 |
|
| 2019 |
Brandjes BD, Davila ML. Adding chimeric antigen receptor-induced killer cells to the medical oncology shelf. The Journal of Clinical Investigation. PMID 31638599 DOI: 10.1172/Jci132536 |
0.484 |
|
| 2019 |
Hashmi H, Bachmeier C, Chavez JC, Song J, Hussaini M, Krivenko G, Nishihori T, Kotani H, Davila ML, Locke FL, Jain MD. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology. PMID 31410842 DOI: 10.1111/Bjh.16155 |
0.457 |
|
| 2019 |
Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. International Journal of Radiation Oncology, Biology, Physics. PMID 31175906 DOI: 10.1016/J.Ijrobp.2019.05.065 |
0.486 |
|
| 2019 |
Logue JM, Krivenko GS, Larson V, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Lazaryan A, Liu HD, Pinilla-Ibarz J, Shah BD, Dholaria BR, Jain MD, Locke FL. Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E14019 |
0.479 |
|
| 2019 |
Dean E, Lu H, Lazaryan A, Krivenko GS, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma. Journal of Clinical Oncology. 37: 7562-7562. DOI: 10.1200/Jco.2019.37.15_Suppl.7562 |
0.481 |
|
| 2019 |
Jain MD, Zhao H, Atkins R, Menges MA, Pope CR, Faramand R, Lee SB, Boucher JC, Kotani H, Bachmeier CA, Chavez J, Shah B, Hussaini M, Gonzalez RJ, Mullinax JE, ... Davila ML, et al. Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma Blood. 134: 2885-2885. DOI: 10.1182/Blood-2019-131041 |
0.477 |
|
| 2019 |
Jain MD, Faramand R, Staedtke V, Bai R, Lee SB, Kotani H, Reid K, Spitler K, Chavez J, Shah B, Bachmeier CA, Dam M, Brandjes B, Gonzalez RJ, Mullinax JE, ... ... Davila ML, et al. The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy Blood. 134: 4105-4105. DOI: 10.1182/Blood-2019-127305 |
0.453 |
|
| 2019 |
Hashmi H, Darwin A, Bachmeier CA, Chavez J, Shah B, Ibarz JP, Nishihori T, Khimani F, Lazaryan A, Liu HD, Davila ML, Locke FL, Jain MD. Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma Blood. 134: 1612-1612. DOI: 10.1182/Blood-2019-126148 |
0.442 |
|
| 2019 |
Shrestha B, Walton K, Reff J, Sagatys EM, Tu N, Boucher JC, Ghafoor T, Pidala J, Blazar BR, Anasetti C, Betts BC, Davila ML. Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia Blood. 134: 196-196. DOI: 10.1182/Blood-2019-124031 |
0.479 |
|
| 2019 |
Boucher JC, Li G, Kotani H, Cabral M, Morrissey D, Lee SB, Spitler K, Beatty N, Shrestha B, Yu B, Kazi A, Wang X, Sebti S, Davila ML. Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function Blood. 134: 248-248. DOI: 10.1182/Blood-2019-122954 |
0.398 |
|
| 2019 |
Cervantes EV, Boucher JC, Lee SB, Spitler K, Reid K, Davila ML. MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption Blood. 134: 4438-4438. DOI: 10.1182/Blood-2019-122752 |
0.42 |
|
| 2019 |
Kotani H, Faramand R, Lee SB, Yu B, Morrissey D, Locke FL, Jain MD, Chavez JC, Wang X, Mishra A, Bachmeier CA, Brentjens RJ, Yoo S, Park JH, Davila ML. Prediction of toxicity in R/R DLBCL treated with Axicabtagene Clioleucel (19-28z CAR T) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz339 |
0.4 |
|
| 2019 |
Kotani H, Li G, Yao J, Mesa TE, Chen J, Yu B, Boucher JC, Yoder SJ, Zhou J, Davila ML. Aged donor derived CAR-T exhibits enhanced effector functions but shorter persistence and less memory-like phenotypes Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz338.067 |
0.478 |
|
| 2019 |
Faramand R, Kotani H, Morrissey D, Yu B, Locke FL, Jain M, Chavez JC, Wang X, Mishra A, Bachmeier CA, Brentjens R, Yoo S, Park J, Davila ML. Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.827 |
0.362 |
|
| 2018 |
Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 564: 273-277. PMID 30542164 DOI: 10.1038/S41586-018-0774-Y |
0.347 |
|
| 2018 |
Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, ... ... Davila ML, et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell. PMID 30392958 DOI: 10.1016/J.Cell.2018.10.001 |
0.424 |
|
| 2018 |
Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, Davila ML. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. Jci Insight. 3. PMID 30232281 DOI: 10.1172/Jci.Insight.121322 |
0.492 |
|
| 2018 |
Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, et al. Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular Therapy. Methods & Clinical Development. 10: 371-378. PMID 30211249 DOI: 10.1016/J.Omtm.2018.08.006 |
0.335 |
|
| 2018 |
Davila ML. CAR T cells find strength in polyfunction. Blood. 132: 769-770. PMID 30139827 DOI: 10.1182/Blood-2018-06-858712 |
0.42 |
|
| 2018 |
Brentjens R, Davila ML. CAR T cells, immunologic and cellular therapies in hematologic malignancies. Best Practice & Research. Clinical Haematology. 31: 115-116. PMID 29909911 DOI: 10.1016/J.Beha.2018.05.001 |
0.455 |
|
| 2018 |
Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. PMID 29703727 DOI: 10.3324/Haematol.2017.186742 |
0.429 |
|
| 2018 |
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England Journal of Medicine. 378: 449-459. PMID 29385376 DOI: 10.1056/Nejmoa1709919 |
0.404 |
|
| 2018 |
Jain MD, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila ML, Liu HD, Falchook AD, Robinson T, Kim S, Locke FL. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel Blood. 132: 4220-4220. DOI: 10.1182/Blood-2018-99-117133 |
0.414 |
|
| 2018 |
Faramand R, Kotani H, Morrissey D, Yu B, Locke FL, Jain MD, Chavez JC, Wang X, Mishra A, Bachmeier CA, Brentjens RJ, Yoo S, Park JH, Davila ML. Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements Blood. 132: 95-95. DOI: 10.1182/Blood-2018-99-116539 |
0.364 |
|
| 2018 |
Kotani H, Li G, Yao J, Mesa TE, Chen J, Boucher JC, Yoder SJ, Zhou J, Davila ML. Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes Blood. 132: 2047-2047. DOI: 10.1182/Blood-2018-99-115351 |
0.509 |
|
| 2018 |
Brayer JB, Sallman DA, Kerre T, Poire X, Havelange V, Lewalle P, Wang ES, Selleslag D, Anguille S, Beguin Y, Purev E, Al-Homsi A, Dekker D, Breman E, Sotiropoulou PA, ... ... Davila ML, et al. Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia Blood. 132: 1398-1398. DOI: 10.1182/Blood-2018-99-114747 |
0.378 |
|
| 2018 |
Sallman DA, Kerre T, Poire X, Havelange V, Lewalle P, Davila ML, Wang ES, Dekker D, Snykers S, Sotiropoulou PA, Breman E, Braun N, Lonez C, Verma B, Lehmann FF, et al. Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy Blood. 132: 902-902. DOI: 10.1182/Blood-2018-99-111326 |
0.35 |
|
| 2018 |
Boucher JC, Li G, Shrestha B, Cabral M, Morrissey D, Guan L, Davila ML. Mutation of the CD28 Costimulatory Domain Confers Decreased CAR T Cell Exhaustion Blood. 132: 966-966. DOI: 10.1182/Blood-2018-99-110645 |
0.497 |
|
| 2018 |
Sallman DA, Brayer JB, Poire X, Kerre T, Lewalle P, Wang ES, Verma B, Breman E, Davila M, Braun N, Lonez C, Gilham DE, Lehmann FF. Abstract CT129: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct129 |
0.437 |
|
| 2018 |
Zhang Y, Yu B, Tsai H, Li G, Hopewell E, Kelley L, Davila ML. A Clinical Grade Cell Based Artificial APC, APC/aCD3/aCD28/Hbd, for High Quality hCD19 CAR-T Expansion and Gene Transduction Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.110 |
0.404 |
|
| 2017 |
Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, et al. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. Bmj Open. 7: e017075. PMID 29133316 DOI: 10.1136/Bmjopen-2017-017075 |
0.396 |
|
| 2017 |
Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leukemia & Lymphoma. 1-5. PMID 29043880 DOI: 10.1080/10428194.2017.1390237 |
0.431 |
|
| 2017 |
Jain MD, Davila ML. Emerging Principles from the Clinical Application of Chimeric Antigen Receptor (CAR) T Cell Therapies for B Cell Malignancies. Stem Cells (Dayton, Ohio). PMID 29024301 DOI: 10.1002/Stem.2715 |
0.518 |
|
| 2017 |
Sallman DA, Davila ML. Is Disease-Specific Immunotherapy a Potential Reality for MDS? Clinical Lymphoma, Myeloma & Leukemia. 17: S26-S30. PMID 28760299 DOI: 10.1016/J.Clml.2017.03.292 |
0.361 |
|
| 2017 |
Locke FL, Davila ML. Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapy. Expert Opinion On Biological Therapy. PMID 28454503 DOI: 10.1080/14712598.2017.1322953 |
0.398 |
|
| 2017 |
Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, et al. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. PMID 28104702 DOI: 10.3324/Haematol.2016.153072 |
0.425 |
|
| 2017 |
Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nature Medicine. PMID 28067900 DOI: 10.1038/Nm.4258 |
0.522 |
|
| 2017 |
Li G, Park K, Davila ML. Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer. Methods in Molecular Biology (Clifton, N.J.). 1514: 111-118. PMID 27787796 DOI: 10.1007/978-1-4939-6548-9_9 |
0.459 |
|
| 2017 |
Davila ML. The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias Journal of the Advanced Practitioner in Oncology. 8. DOI: 10.6004/Jadpro.2017.8.6.10 |
0.464 |
|
| 2017 |
Li G, Beatty N, Vishwasrao P, Boucher JC, Yu B, Park K, Zhang Y, Davila ML. Mouse CD19-Targeted Chimeric Antigen Receptors That Include a 41BB Co-Stimulatory Domain Induce NFkB Signaling to Enhance T Cell Proliferation, Viability, and Leukemia Killing Blood. 130: 843-843. DOI: 10.1182/Blood.V130.Suppl_1.843.843 |
0.538 |
|
| 2017 |
Boucher JC, Vishwasrao P, Guan L, Shrestha B, Li G, Christley S, Cowell LG, Ostmeyer J, Rounds WH, Toby IT, Davila ML. Next Generation Sequencing of Immunized Mouse Splenocytes to Develop an Anti-TIM3 Chimeric Antigen Receptor for Acute Myeloid Leukemia Blood. 130: 2646-2646. DOI: 10.1182/Blood.V130.Suppl_1.2646.2646 |
0.471 |
|
| 2017 |
Boucher JC, Davila ML. Co-Stimulatory Regulation of CAR T Cell Function Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.08.026 |
0.432 |
|
| 2017 |
Li G, Beatty N, Vishwasrao P, Yu B, Park P, Zhang Y, Davila ML. Optimization of Murine 4-1BB Signaling Results in Enhanced CD19-Targeted CAR T Cell Function in Immune Competent Mice Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.417 |
0.41 |
|
| 2016 |
Davila ML, Brentjens RJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clinical Advances in Hematology & Oncology : H&O. 14: 802-808. PMID 27930631 |
0.479 |
|
| 2016 |
Oluwole OO, Davila ML. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. Journal of Leukocyte Biology. PMID 27354412 DOI: 10.1189/jlb.5BT1115-524R |
0.445 |
|
| 2016 |
Davila ML, Sadelain M. Biology and clinical application of CAR T cells for B cell malignancies. International Journal of Hematology. PMID 27262700 DOI: 10.1007/S12185-016-2039-6 |
0.523 |
|
| 2016 |
Abate-Daga D, Davila ML. CAR models: next-generation CAR modifications for enhanced T-cell function. Molecular Therapy Oncolytics. 3: 16014. PMID 27231717 DOI: 10.1038/Mto.2016.14 |
0.484 |
|
| 2016 |
Locke FL, Davila ML. Chimeric antigen receptor T cells get passed by leukemia Translational Cancer Research. 5. DOI: 10.21037/8530 |
0.551 |
|
| 2016 |
Smith M, Ghosh A, James S, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Schietinger A, Sadelain MW, Brink Mvd. Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease Blood. 128: 653-653. DOI: 10.1182/Blood.V128.22.653.653 |
0.51 |
|
| 2015 |
Davila ML, Sauter C, Brentjens R. CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date. Cancer Journal (Sudbury, Mass.). 21: 470-4. PMID 26588678 DOI: 10.1097/Ppo.0000000000000153 |
0.519 |
|
| 2015 |
Bouhassira DC, Thompson JJ, Davila ML. Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opinion On Biological Therapy. 15: 403-16. PMID 25666545 DOI: 10.1517/14712598.2015.1014792 |
0.529 |
|
| 2015 |
Davila ML, Sauter C, Brentjens R. CD19-targeted t cells for hematologic malignancies clinical experience to date Cancer Journal (United States). 21: 470-474. |
0.428 |
|
| 2014 |
Davila ML, Papapetrou EP. CARs Move To the Fast Lane. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 477-478. PMID 28141992 DOI: 10.1038/Mt.2014.8 |
0.497 |
|
| 2014 |
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine. 6: 224ra25. PMID 24553386 DOI: 10.1126/Scitranslmed.3008226 |
0.53 |
|
| 2014 |
Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. International Journal of Hematology. 99: 361-71. PMID 24311149 DOI: 10.1007/S12185-013-1479-5 |
0.515 |
|
| 2014 |
Park JH, Riviere I, Wang X, Bernal YJ, Yoo S, Purdon T, Halton E, Quintanilla H, Curran KJ, Sauter CS, Davila ML, Sadelain M, Brentjens RJ. CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL Blood. 124: 382-382. DOI: 10.1182/Blood.V124.21.382.382 |
0.498 |
|
| 2014 |
Sadelain M, Brentjens R, Davila M, Riviere I, Wang X, Bartido S, Park J, Bouhassira D, Curran K, Chung S, Stefanski J, Borquez-Ojeda O, Giralt S. Abstract CT102: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct102 |
0.54 |
|
| 2013 |
Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. Plos One. 8: e61338. PMID 23585892 DOI: 10.1371/Journal.Pone.0061338 |
0.505 |
|
| 2013 |
Davila ML, Brentjens R. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? Hematology/Oncology Clinics of North America. 27: 341-53. PMID 23561477 DOI: 10.1016/J.Hoc.2012.12.004 |
0.502 |
|
| 2013 |
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Translational Medicine. 5: 177ra38. PMID 23515080 DOI: 10.1126/Scitranslmed.3005930 |
0.546 |
|
| 2013 |
Davila ML, Brentjens R. Early Clinical Outcomes of Chimeric Antigen Receptor Modified T Cells and the Generation of "Armored" CAR T Cells for Future Applications to Cancer Immunotherapy Aacr Education Book. 2013: 71-76. DOI: 10.1158/AACR.EDB-13-7842 |
0.337 |
|
| 2012 |
Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 1: 1577-1583. PMID 23264903 DOI: 10.4161/Onci.22524 |
0.524 |
|
| 2012 |
Davila ML, Riviere I, Wang X, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, Frattini MG, Sadelain M, Brentjens RJ. A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL). Journal of Clinical Oncology. 30: TPS2619-TPS2619. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps2619 |
0.546 |
|
| 2012 |
Ghosh A, Davila ML, Young LF, Kloss C, Gunset G, Smith OM, West ML, Singer NV, Holland AM, Jenq RR, Hanash AM, Dudakov JA, Velardi E, Shono Y, Sadelain M, et al. CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd Blood. 120: 451-451. DOI: 10.1182/Blood.V120.21.451.451 |
0.503 |
|
| 2012 |
Davila ML, Riviere I, Wang X, Park JH, Stefanski J, Taylor C, He Q, Olszewska M, Wasielewska T, Borquez-Ojeda O, Qu J, Bartido S, Jurcic JG, Douer D, Frattini MG, et al. Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells Blood. 120: 3566-3566. DOI: 10.1182/Blood.V120.21.3566.3566 |
0.554 |
|
| 2012 |
Davila ML, Kloss C, Brentjens RJ, Sadelain M. Conditioning Intensity and T Cell Dose Determine Efficacy of CD19-Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL. Blood. 120: 2613-2613. DOI: 10.1182/Blood.V120.21.2613.2613 |
0.544 |
|
| 2012 |
Park JH, Rivière I, Wang X, Stefanski J, He Q, Taylor C, Olszewska M, Wasielewska T, Bartido S, Davila ML, Bernal Y, Lamanna N, Noy A, Sadelain M, Brentjens RJ. Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL Blood. 120: 1797-1797. DOI: 10.1182/Blood.V120.21.1797.1797 |
0.521 |
|
| 2011 |
Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118: 4817-28. PMID 21849486 DOI: 10.1182/Blood-2011-04-348540 |
0.551 |
|
| 2010 |
Davila ML, Taylor C, Wang X, Stefanski J, Olszewska M, Bartido S, Frattini M, Sadelain M, Rivière I, Brentjens RJ. B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen Blood. 116: 3268-3268. DOI: 10.1182/Blood.V116.21.3268.3268 |
0.548 |
|
| 2010 |
Davila ML, Sadelain M. T Cells Genetically Targeted to CD19 Eradicate B-ALL In a Novel Syngeneic Mouse Disease Model Blood. 116: 171-171. DOI: 10.1182/Blood.V116.21.171.171 |
0.526 |
|
| 2009 |
Lieberman AE, Kuraoka M, Davila M, Kelsoe G, Cowell LG. Conserved cryptic recombination signals in Vkappa gene segments are cleaved in small pre-B cells. Bmc Immunology. 10: 37. PMID 19555491 DOI: 10.1186/1471-2172-10-37 |
0.712 |
|
| 2007 |
Davila M, Liu F, Cowell LG, Lieberman AE, Heikamp E, Patel A, Kelsoe G. Multiple, conserved cryptic recombination signals in VH gene segments: detection of cleavage products only in pro B cells. The Journal of Experimental Medicine. 204: 3195-208. PMID 18056287 DOI: 10.1084/Jem.20071224 |
0.627 |
|
| 2004 |
Cowell LG, Davila M, Ramsden D, Kelsoe G. Computational tools for understanding sequence variability in recombination signals. Immunological Reviews. 200: 57-69. PMID 15242396 DOI: 10.1111/J.0105-2896.2004.00171.X |
0.546 |
|
| 2003 |
Cowell LG, Davila M, Yang K, Kepler TB, Kelsoe G. Prospective estimation of recombination signal efficiency and identification of functional cryptic signals in the genome by statistical modeling. The Journal of Experimental Medicine. 197: 207-20. PMID 12538660 DOI: 10.1084/Jem.20020250 |
0.607 |
|
| 2002 |
Cowell LG, Davila M, Kepler TB, Kelsoe G. Identification and utilization of arbitrary correlations in models of recombination signal sequences. Genome Biology. 3: RESEARCH0072. PMID 12537561 DOI: 10.1186/Gb-2002-3-12-Research0072 |
0.479 |
|
| 2001 |
Davila M, Foster S, Kelsoe G, Yang K. A role for secondary V(D)J recombination in oncogenic chromosomal translocations? Advances in Cancer Research. 81: 61-92. PMID 11430596 DOI: 10.1016/S0065-230X(01)81002-2 |
0.673 |
|
| 1999 |
Yang K, Davila M, Kelsoe G. Do germinal centers have a role in the generation of lymphomas? Current Topics in Microbiology and Immunology. 246: 53-60; discussion 61. PMID 10396039 DOI: 10.1007/978-3-642-60162-0_7 |
0.597 |
|
| Show low-probability matches. |